These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1102242)

  • 41. News from the Society for Women's Health Research: FDA doing poor job of monitoring drugs for sex differences.
    Greenberger P
    J Womens Health Gend Based Med; 2001 Nov; 10(9):829-30. PubMed ID: 11747675
    [No Abstract]   [Full Text] [Related]  

  • 42. Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths.
    Serebruany VL; Fortmann SD; Cherepanov V; Litvinov O; Kim MH; Marciniak TA
    Am J Med; 2017 Jun; 130(6):e245-e246. PubMed ID: 28161342
    [No Abstract]   [Full Text] [Related]  

  • 43. [How to improve drug development and utilization in pediatrics].
    Pons G; Lassale C; Eschwege E
    Therapie; 1999; 54(4):423-32. PubMed ID: 10667109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IOM advises FDA on ethics in postmarket safety trials.
    Kuehn BM
    JAMA; 2010 Aug; 304(6):627. PubMed ID: 20699450
    [No Abstract]   [Full Text] [Related]  

  • 45. Restoring confidence in the pharmaceutical industry.
    Bauchner H; Fontanarosa PB
    JAMA; 2013 Feb; 309(6):607-9. PubMed ID: 23403686
    [No Abstract]   [Full Text] [Related]  

  • 46. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA.
    Miller JL
    Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122
    [No Abstract]   [Full Text] [Related]  

  • 47. The promise of pharmacoepidemiology.
    Strom BL
    Annu Rev Pharmacol Toxicol; 1987; 27():71-86. PubMed ID: 3555321
    [No Abstract]   [Full Text] [Related]  

  • 48. Premarketing adverse drug experiences: data management procedures. Unexpected death occurring early in clinical trials.
    Cato A
    Drug Inf J; 1987; 21(1):3-7. PubMed ID: 10281637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The FDA Safety and Innovation Act.
    Steinbrook R; Sharfstein JM
    JAMA; 2012 Oct; 308(14):1437-8. PubMed ID: 23047356
    [No Abstract]   [Full Text] [Related]  

  • 50. IOM: overhaul drug safety monitoring.
    Kuehn BM
    JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
    [No Abstract]   [Full Text] [Related]  

  • 51. Medication decisions--right and wrong.
    Stuart B; Briesacher B
    Med Care Res Rev; 2002 Jun; 59(2):123-45. PubMed ID: 12053819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Institute of Medicine's report on drug safety: constructive and ambitious, but does it go far enough?
    Jones JK
    Clin Pharmacol Ther; 2007 Feb; 81(2):156-8. PubMed ID: 17259940
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can postmarketing surveillance help to effect optimal drug therapy?
    Strom BL; Melmon KL
    JAMA; 1979 Nov; 242(22):2420-2. PubMed ID: 385922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonprescription drugs: an overview.
    Hodes B
    Int J Health Serv; 1974; 4(1):125-30. PubMed ID: 4829892
    [No Abstract]   [Full Text] [Related]  

  • 55. FDA introductory comments: clinical studies design and evaluation issues.
    Woodcock J
    Clin Trials; 2005; 2(4):273-5. PubMed ID: 16281424
    [No Abstract]   [Full Text] [Related]  

  • 56. Comment on 'The ethics of animal research' by Festing & Wilkinson.
    Archibald K; Clotworthy M
    EMBO Rep; 2007 Sep; 8(9):794-6; author reply 796-7. PubMed ID: 17767185
    [No Abstract]   [Full Text] [Related]  

  • 57. European drug agency under fire: critics charge that trial data are too inaccessible.
    Hampton T
    JAMA; 2011 Aug; 306(6):593-5. PubMed ID: 21828315
    [No Abstract]   [Full Text] [Related]  

  • 58. Gender-based differences in the toxicity of pharmaceuticals--the Food and Drug Administration's perspective.
    Miller MA
    Int J Toxicol; 2001; 20(3):149-52. PubMed ID: 11488556
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A proposal for radical changes in the drug-approval process.
    Wood AJ
    N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
    [No Abstract]   [Full Text] [Related]  

  • 60. Controversy trails adaptive clinical trials.
    Goozner M
    J Natl Cancer Inst; 2012 Sep; 104(18):1347-8. PubMed ID: 22984199
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.